Core Viewpoint - Lantheus Holdings (NASDAQ: LNTH) presents a strong investment case driven by its flagship product Pylarify, which is a leading imaging agent in a growing market, alongside its established product Definity for echocardiograms [1] Product Analysis - Pylarify is recognized as a best-in-class imaging agent, indicating its competitive advantage in the market [1] - Definity has a long-standing history of market leadership, suggesting stability and reliability in its performance [1] Market Context - The market for imaging agents is expected to grow, which could benefit Lantheus Holdings significantly due to its strong product offerings [1]

Core Viewpoint - Investors should focus on pharmaceutical stocks that are currently trading at extremely oversold levels, as indicated by the Relative Strength Index (RSI), which can signal potential rebounds [1][13]. Group 1: Sarepta Therapeutics - Sarepta Therapeutics has an RSI of 22, indicating extreme oversold conditions, and has seen its stock price drop over 40% following an earnings miss [2][3]. - The 12-month stock price forecast for Sarepta is $131.22, suggesting a potential upside of 262.48% from the current price of $36.20 [2]. - Analysts, including those from Wells Fargo, maintain a Buy rating and are optimistic about Sarepta's long-term pipeline, particularly its FDA-approved gene therapy for Duchenne muscular dystrophy [3][4]. Group 2: Krystal Biotech - Krystal Biotech's RSI has risen to 33, indicating a recovery from oversold levels, with a recent stock price of $134.53 [5][6]. - The 12-month stock price forecast for Krystal is $218.63, representing a potential upside of 62.51% [5]. - Analysts remain bullish on Krystal, with Guggenheim reiterating a Buy rating and a price target of $189, indicating nearly 40% upside potential [7][8]. Group 3: Lantheus Holdings - Lantheus Holdings has an RSI of 28, showing signs of being oversold after a 25% drop following an earnings miss [9][10]. - The 12-month stock price forecast for Lantheus is $132.67, suggesting a potential upside of 68.04% from the current price of $78.95 [9]. - Truist Financial has reiterated a Buy rating with a price target of $117, indicating more than 45% upside potential, supported by the company's strong product portfolio [11][10].